Endocrinology
From the Journals
SGLT2 inhibitor use rising in patients with DKD
News
Empagliflozin gets HFrEF approval from FDA
The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes...
From the Journals
Pandemic derails small success in lowering diabetes-related amputations
Minor diabetes-related lower extremity amputations increased at the expense of major amputations in some groups to 2017, but COVID-19 has likely...
News
FDA approves rapid-acting insulin, Lyumjev, for pump use
Approved for diabetes treatment last year, it’s the second ultra-rapid-acting insulin approved for use in insulin delivery devices.
News
FDA clears app for FreeStyle Libre 2 glucose monitor
System includes optional alarms; app allows for remote monitoring.
Conference Coverage
ESC heart failure guideline to integrate bounty of new meds
It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds...
From the Journals
PCPs lag on albuminuria tests in patients with type 2 diabetes
News
ACC issues decision pathway for hypertriglyceridemia management
“In light of the controversies regarding the REDUCE-IT trial, the writing committee has done a nice job with providing useful guidance regarding...
From the Journals
ARBs equal ACE inhibitors for hypertension, and better tolerated
Although ACE inhibitors are more commonly prescribed, new findings from almost 3 million patients support starting with ARBs as first-time...
From the Journals
Diabetes duration linked to increasing heart failure risk
Diabetes duration of 15 years or more is tied to a tripled incident heart failure rate, 20-year follow-up on nearly 10,000 U.S. adults shows.
From the Journals
Dapagliflozin safe, protective in advanced kidney disease
“This is now the absolute reassurance that we do not have to stop an SGLT2 inhibitor in people with eGFR< 30 mL/min for safety reasons” and...